Mode of presentation and time to treatment of uveal melanoma in Finland

Aims: To investigate the current referral pattern and delays in treatment of patients with primary uveal melanoma. Methods: 184 consecutive Finnish patients with uveal melanoma diagnosed between July 1994 and June 1999 were eligible, and 159 were enrolled (inclusion rate, 86%). Their mean age was 60...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of ophthalmology 2002-03, Vol.86 (3), p.333-338
Hauptverfasser: Eskelin, S, Kivelä, T
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Aims: To investigate the current referral pattern and delays in treatment of patients with primary uveal melanoma. Methods: 184 consecutive Finnish patients with uveal melanoma diagnosed between July 1994 and June 1999 were eligible, and 159 were enrolled (inclusion rate, 86%). Their mean age was 60 years (range 14–87). The dates of visits to dispensing optician, physician, ophthalmologist and ocular oncologist, the presence of symptoms, and reason for consultation were determined by structured telephone interview. Time intervals to treatment planning and treatment were calculated. Results: 139 patients (87%) had symptoms at presentation and 44 patients (28%) had been seen by an ophthalmologist less than 2 years previously. The median height of the tumour was 6 mm (range, 1.0–17.0) and its largest basal diameter 11 mm (range 2.5–22.0) at diagnosis. Melanoma developed from a previously detected presumed naevus in 13 patients (8%). When the first contact was a dispensing optician (15%) the median time to treatment planning was 22 days (range 1–1156). When a physician other than an ophthalmologist (19%) was contacted the delay was 68 days (range 0–1283) and when an ophthalmologist (65%) was seen it was 34 days (range 1–1426). These differences were not significant (p=0.32). The chance of being referred at first visit was 89%. Median time to treatment was not associated with symptoms (p=0.16) and tumour volume (p=0.29), but it was significantly different between patients who were and were not referred at first visit (140 days v 34 days; p
ISSN:0007-1161
1468-2079
DOI:10.1136/bjo.86.3.333